Molecular Tumor Board: 39 year old female with history of advanced stage squamous cell cervical cancer, new lung mass and PIK3CA mutation

For patients who present with advanced stage cervical cancer, targeted therapies can improve outcomes. Join us for a molecular tumor board as we discuss treatment options for patients with recurrent cervical cancer and how biomarker-directed therapies are transforming the standard of care.

Association of antifolate response signature status and clinical activity of pemetrexed platinum chemotherapy in non-small cell lung cancer - The Piedmont Study

Molecular Tumor Board: 69-year-old male with metastatic urothelial carcinoma with FGFR3 mutation

Labcorp Finalizes Strategic Relationship with Jefferson Health

BURLINGTON, N.C. , July 13, 2023 /PRNewswire/ --  Labcorp (NYSE: LH), a global leader in innovative and comprehensive laboratory services, today announced the completion of the previously announced transaction that establishes a strategic relationship with Jefferson Health (Jefferson), the largest

Labcorp Declares Quarterly Dividend

BURLINGTON, N.C. , July 13, 2023 /PRNewswire/ --  Labcorp  (NYSE: LH), a leading global life sciences company, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock. The dividend will be payable on September 8, 2023 , to stockholders of record

Labcorp and Legacy Health agree to comprehensive laboratory relationship

Agreement Will Expand Access to Labcorp's Diagnostics Capabilities and Improve Services BURLINGTON, N.C. , July 11, 2023 /PRNewswire/ --  Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced that it has entered into an agreement with Legacy Health  

Labcorp completes spin-off of Fortrea

BURLINGTON, N.C. , July 3, 2023 /PRNewswire/ --  Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced that it has completed the spin-off of Fortrea, the newly formed independent Contract Research Organization providing Phase I-IV clinical trial

Sex-specific effects of body composition on tumor microenvironment in non–small cell lung cancer